Qcdx LLC

Innovative technology that reliably detects dysplasia and makes cancer prevention possible. CDx provides an integrated solution of enhanced tissue sampling and an AI-assisted diagnostic platform. Advanced 3D imaging and analysis provide a unique view of the tissue. All this provides patients and their physicians with reliable diagnostic testing based on the most advanced science available. Let us help you with questions about our products and services.

We are developing non-invasive screening methods to detect cancer early and save lives. Our mission is to expand cancer screening by providing non-invasive, low cost diagnostic tests through our DiNanoQ™ blood test and a suite of data products available on our diagnostic dashboard. We provide non-invasive, affordable and scalable methods to expand cancer screening. We provide a suite of data products that aid clinicians in their treatment decisions. Dysplasia Diagnostics Limited is a UK-based company developing AI-based solutions for profiling molecular events in the blood that are associated with changes in the early stages of cancer. Furthermore, in our drive to develop better solutions, we are supported by other scientists and consultants, who are experts in their fields. Tracking some of these messages is the primary objective of recent efforts to detect cancer early, as scalable methods for early cancer detection that are noninvasive and only profile biomolecules in bio fluids have emerged. To address some of the weaknesses of other approaches, we are developing an AI-based diagnostic system that profiles platelets RNA for rare molecular events indicative of the carcinogenic process and provides information about the diseased tissue and stage.

We develop diagnostic tests that identify the unique properties of each patients’ cancer to inform clinicians on how best to manage their disease. We are dedicated to developing valuable tools for precision medicine. To develop and offer state-of-the-art diagnostic tests to provide patients exemplary personalized cancer care. Qualisure Diagnostics is dedicated to creating those tools. We believe that patients with cancer are individuals, and treatments can be personalized. Oliver Bathe, MD is a surgical oncologist and professor of surgery and oncology at the University of Calgary. Cynthia Stretch, PhD is a cancer biologist and a bioinformatician. Farshad Farshidfar, MD, PhD is a computational biologist.

Our mission is to deliver diagnostic excellence and precision accuracy. We provide a wide array of pathology tests at the request of providers, nurses, and PAs. QDx Pathology Services is a national, independent, full-service molecular and anatomical pathology laboratory dedicated to providing diagnostic excellence to our customers and their patients. Our CLIA and CAP certified laboratory utilizes the latest in state-of-the-art instrumentation and information technology. The Company operates 7 days per week to ensure rapid availability of consultations and diagnostic information. Since 2006, QDx has delivered diagnostic excellence with concierge-level account management and board-certified pathologists' live peer-to-peer consultation. QDx Pathology® Services is a national, independent, full-service molecular and anatomical pathology laboratory dedicated to providing diagnostic excellence to our customers and their patients. Our CLIA and CAP-certified laboratory utilizes the latest in state-of-the-art instrumentation and information technology.

OncoCDx is a not for profit socially responsible research organization established by researchers from the top institutes and universities in the world, including University of Cambridge, UK, Oxford, UK and California Berkeley, USA. Our mission is to provide doctors with the most comprehensive equipment and patients with more personalized diagnostics. OncoCDx is an innovative and reliable business partner. We believe survival is the general human right no matter of the race, ethnicity, ability, nationality, wealth, and gender. As a team of experts, they are competent and easily adapt to a rapidly changing environment. A&A Biotechnology is satisfied with the professional service provided by the company and fully recommend the team to work with.

We are driven forward by a vision of a future where cancer is curable. We are developing blood tests that detect cancer in its earliest stages so we can transform cancer into a disease that’s preventable and curable. We are applying our multi-omics, computational biology and machine learning approach to capture cancer’s signal for high-burden gastrointestinal cancers. Starting with colorectal cancer, we are building a multi-cancer platform that can identify the unique DNA regions associated with different types of cancers. Cancer’s early detection has become one of the greatest challenges of modern medicine, so we decided to team up with the best. Our company was founded on Silicon Valley’s ideals of technology and development (Singularity University), and we developed a network of world-class R&D partners including Quest Diagnostics and Hologic (Diagenode). Our Scientific Advisory Board includes leading oncologists, gastroenterologists and business experts from the US and Europe. We have built a network of >100 hospitals in the U.S.